Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.48 |
| ▸ | JAK1 | P23458 | 18/20 | 0.48 |
| ▸ | TYK2 | P29597 | 18/20 | 0.48 |
| ▸ | JAK3 | P52333 | 18/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920235 | 0.84 | CSF1R (0.52) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9923039 | 0.78 | JAK3 (0.47) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9920229 | 0.78 | JAK3 (0.45) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9920209 | 0.77 | JAK3 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9918540 | 0.72 | EGFR (0.42) | JAK2JAK1JAK3ROCK2EGFR | |
| SCHEMBL9920207 | 0.71 | JAK3 (0.45) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1160541 | 0.71 | JAK1 (0.60) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9920240 | 0.70 | JAK2 (0.50) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9923296 | 0.69 | JAK2 (0.47) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9920241 | 0.69 | JAK2 (0.47) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.